SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments
2 references·4 citing·22 second hop
Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments (2018)Addressing the Value of Gene Therapy and …Legislating against Use of Cost-Effectiveness Information (2010)Legislating against Use of Co…QALYs: The Basics (2009)QALYs: The BasicsFinancing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options (2022)Financing and Reimbursement M…Human gene therapy: A patent analysis (2021)Human gene therapy: A patent …Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs (2020)Orphan Drugs Offer Larger Hea…Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions (2020)Market access of gene therapi…Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)The economic value of personalized medicine tests: what we know and what we need to know (2013)Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries (2014)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)A utility maximization model for evaluation of health care programs. (1972)Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)Making Descriptive Use of Prospect Theory to Improve the Prescriptive Use of Expected Utility (2001)Conceptualizing a Model (2012)Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)Assetization (2020)Board of Governors of the Federal Reserve System (2001)Bias in published cost effectiveness studies: systematic review (2006)Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers (2010)Advanced therapy medicinal products: current and future perspectives (2016)Overcoming Challenges Facing Advanced Therapies in the EU Market (2016)Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Patentability of Genes: A European Union Perspective (2014)The dual frontier: Patented inventions and prior scientific advance (2017)Science quality and the value of inventions (2019)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Delivering affordable cancer care in high-income countries (2011)De-duplication of database search results for systematic reviews in EndNote (2016)
this work references cited by second hop

References

  • 2009QALYs: The Basics757 cited
  • 2010Legislating against Use of Cost-Effectiveness Information251 cited

Cited by

  • 2022Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options65 cited
  • 2020Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs58 cited
  • 2020Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions53 cited
  • 2021Human gene therapy: A patent analysis18 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work